Picture of Collegium Pharmaceutical logo

COLL — Collegium Pharmaceutical News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedMid CapSuper Stock

Collegium Pharmaceutical Inc expected to post earnings of 31  cents a share - Earnings Preview

* Collegium Pharmaceutical Inc  COLL.OQ   COLL.O  is
expected
to show a rise in quarterly revenue when it reports  results on
May 4. 
    * The Stoughton Massachusetts-based  company is expected to
report
 a 65.3% increase in revenue to $138.466 million from $83.75
million a year ago, according to the mean estimate from 6
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Collegium
Pharmaceutical
Inc is for earnings of 31 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 29.3%
in the last three months. ​
    * Wall Street's median 12-month price target for Collegium
Pharmaceutical Inc is $35​, above​ its last closing price
of $22.30. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.04       -0.14      -0.21     Missed  -44.8
 Sep. 30 2022  -0.19       -0.13      0.01      Beat    107.4
 Jun. 30 2022  1.38        1.42       0.32      Missed  -77.5​
 Mar. 31 2022  0.90        0.90       0.44      Missed  -50.9
 ​​Dec.        1.06        1.04       -0.51     Missed  -149.2
 31 2021                                                
 Sep. 30 2021  0.95        0.95       0.22      Missed  -76.9​
 Jun. 30 2021  0.36        0.47       0.27      Missed  -42.8
 Mar. 31 2021  0.30        0.42       0.41      Missed  -2.8
 This summary was machine generated May 3 at 02:01 GMT.  All
figures in US dollars  unless otherwise stated

Recent news on Collegium Pharmaceutical

See all news